MicroMarvel is a series of articles highlighting undercovered stocks with less than a billion dollars in Market Capitalization. These articles are not intended to be buy recommendations. They highlight stocks that may have limited trading volume and may be highly volatile, so if you do decide to add them to your portfolio I highly recommend you use stop losses and limit orders.

• 100% technical buy signals
• 16 new highs and up 38.79% in the last month
• 94.39+ Weighted Alpha

Today's MicroMarvel is the biopharmaceutical company Tarsus Pharmaceuticals (TARS). I found the stock by using Barchart's screening functions to find stocks with the highest technical buy signals, highest Weighted Alpha, superior current momentum, and having a Trend Seeker buy signal, then used the Flipchart feature to review the charts for consistent price appreciation. Since the Trend Seeker signaled a buy on 11/8 the stock gained 69.17%.

TARS Price vs Daily Moving Averages (Barchart)

Tarsus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea, and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California. 

Barchart Technical Indicators:

• 100% technical buy signals
• 96.20+ Weighted Alpha
• 83.73% gain in the last year
• Trend Seeker buy signal
• Above its 20, 50, and 100-day moving averages
• 15 new highs and up 27.97% in the last month
• Relative Strength Index 78.67%
• Technical support level at $8.86
• Recently traded at $9.24 with a 50-day moving average of $7.57

Fundamental Factors:

• Market Cap $957 million
• Wall Street analysts are projecting Revenue to be down 62.40% this  year but up again by 536.80% next year
• Earnings are estimated to decrease 89.70% this year, down another 2.30% next year and continue to shrink by an annual rate of 20.70% for the next 5 years

Analysts and Investor Sentiment -- I don't buy stocks just because everyone else is buying, but I do realize that if major firms and investors are dumping a stock it's hard to make money swimming against the tide:

• In spite of those gloomy projections Wall Street analysts issued 6 strong buy, 2 buy and 1 hold recommendation this month
• Their price targets are $19 to $60 with a consensus of $45 for another 59% gain in price
• CFRAs MarketScope rates the stock a strong sell - the opposite of the other analysts
• only 991 investors monitor the stock on Seeking Alpha

More By This Author:

Teekay Is Better Than OK
Chart Of The Day: FTAI Aviation - Sky's The Limit
Cardiol Therapeutics - This Penny Stock Is An Analysts Favorite